| answer text |
<p>The Government has set out a vision for the Future of UK Clinical Research Delivery
which aims to increase participation in research and improve the speed and efficiency
of approvals processes. This, together with the Government response to the O’Shaughnessy
review backed by up to £121 million of funding, will help to drive improvements in
recruitment to clinical trials and approval processes which lead to quicker study
set up. More information on the vision is available at the following link:</p><p><a
href="https://www.gov.uk/government/publications/the-future-of-uk-clinical-research-delivery/saving-and-improving-lives-the-future-of-uk-clinical-research-delivery"
target="_blank">https://www.gov.uk/government/publications/the-future-of-uk-clinical-research-delivery/saving-and-improving-lives-the-future-of-uk-clinical-research-delivery</a></p><p>The
Medicines and Healthcare products Regulatory Agency has now cleared the backlog of
clinical trials waiting for regulatory approvals and regulatory assessments, and all
newly received, fully complaint clinical trials applications will be approved within
statutory timelines of 60 days. In the Government response to the O’Shaughnessy review,
we announced new United Kingdom performance indicators with immediate effect, including
measures relating to recruitment levels and approvals timelines for clinical trials.
These measures will benefit all clinical trials, including brain tumour trials.</p><p>The
Department-funded National Institute of Health and Care Research (NIHR) funds research
and research infrastructure which supports patients and the public to participate
in high-quality research. In 2022/23, NIHR supported 61 brain tumour studies and supported
recruitment of 4,317 participants to these studies in England. In addition, the NIHR
online service called 'Be Part of Research' allows users to search for studies and
register their interest that is relevant to them, increasing access to research opportunities.</p>
|
|
